EyePoint Pharmaceuticals Inc.

9.75+0.6100+6.67%Vol 170.00K1Y Perf 12.25%
Apr 13th, 2021 16:00 DELAYED
BID9.75 ASK10.09
Open9.13 Previous Close9.14
Pre-Market- After-Market-
 - -  - -%
Target Price
17.88 
Analyst Rating
Moderate Buy 2.33
Potential %
83.38 
Finscreener Ranking
     41.82
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
     34.48
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★+     50.92
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap280.22M 
Earnings Rating
Neutral
Price Range Ratio 52W %
54.03 
Earnings Date
5th May 2021

Today's Price Range

9.1310.02

52W Range

3.5115.06

5 Year PE Ratio Range

-2.20-2.00

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-8.71%
1 Month
-13.02%
3 Months
-10.96%
6 Months
93.72%
1 Year
12.25%
3 Years
-32.29%
5 Years
-67.72%
10 Years
-78.33%

TickerPriceChg.Chg.%
EYPT9.750.61006.67
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
3.70
4.20
0.68
2.17
-5.30
Leverage Ratio 7.30
ProfitabilityValueIndustryS&P 500US Markets
83.10
-110.70
-103.10
-
-
RevenueValueIndustryS&P 500US Markets
26.95M
0.94
148.15
76.64
Earnings HistoryEstimateReportedSurprise %
Q04 20200.45-1.01-324.44
Q03 2020-0.10-0.30-200.00
Q02 2020-1.10-1.009.09
Q01 2020-1.00-1.10-10.00
Q04 2019-1.20-0.9025.00
Q03 2019-1.40-1.400.00
Q02 2019-0.14-0.1214.29
Q01 2019-0.13-0.19-46.15
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.528.77Positive
6/2021 QR-0.436.52Positive
12/2021 FY-1.71-13.25Negative
12/2022 FY-1.58-125.71Negative
Next Report Date5th May 2021
Estimated EPS Next Report-0.52
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume170.00K
Shares Outstanding28.74M
Trades Count2.11K
Dollar Volume3.02M
Avg. Volume373.05K
Avg. Weekly Volume216.71K
Avg. Monthly Volume264.78K
Avg. Quarterly Volume344.10K

EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) stock closed at 9.75 per share at the end of the most recent trading day (a 6.67% change compared to the prior day closing price) with a volume of 170.17K shares and market capitalization of 280.22M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 84 people. EyePoint Pharmaceuticals Inc. CEO is Nancy Lurker.

The one-year performance of EyePoint Pharmaceuticals Inc. stock is 12.25%, while year-to-date (YTD) performance is 48.18%. EYPT stock has a five-year performance of -67.72%. Its 52-week range is between 3.51 and 15.06, which gives EYPT stock a 52-week price range ratio of 54.03%

EyePoint Pharmaceuticals Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 15.70, a price-to-sale (PS) ratio of 10.68, a price to cashflow ratio of 10.50, a PEG ratio of 2.32, a ROA of -53.04%, a ROC of -53.00% and a ROE of -328.82%. The company’s profit margin is -%, its EBITDA margin is -103.10%, and its revenue ttm is $26.95 Million , which makes it $0.94 revenue per share.

Of the last four earnings reports from EyePoint Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.52 for the next earnings report. EyePoint Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for EyePoint Pharmaceuticals Inc. is Moderate Buy (2.33), with a target price of $17.88, which is +83.38% compared to the current price. The earnings rating for EyePoint Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

EyePoint Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

EyePoint Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.89, ATR14 : 1.23, CCI20 : -103.55, Chaikin Money Flow : -0.17, MACD : -0.49, Money Flow Index : 32.54, ROC : -5.71, RSI : 42.70, STOCH (14,3) : 39.11, STOCH RSI : 0.49, UO : 42.54, Williams %R : -60.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of EyePoint Pharmaceuticals Inc. in the last 12-months were: Dario A. Paggiarino (Option Excercise at a value of $0), David R. Guyer (Option Excercise at a value of $0), David Scott Jones (Option Excercise at a value of $0), Douglas E. Godshall (Option Excercise at a value of $0), George O. Elston (Buy at a value of $10 912), Goran A. Ando (Option Excercise at a value of $0), John B. Landis (Option Excercise at a value of $0), Nancy Lurker (Option Excercise at a value of $0), Wendy F. DiCicco (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
1.67

EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.

CEO: Nancy Lurker

Telephone: +1 617 926-5000

Address: 480 Pleasant Street, Watertown 02472, MA, US

Number of employees: 84

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

50%50%

Bearish Bullish

59%41%

News

Stocktwits